Biotech | May 12, 2022
New two-year Deucravacitinib data show promising results for severe plaque psoriasis
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
